Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alex Nelson

Interventional Pain Medicine Murray, UT Medical Doctor

NPI 1730405408 CMS profile 811253

5801 S Fashion Blvd, Ste. 180, Murray, UT 84107

Open in the dashboard

General payments

$16,581

455 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$29,223 paid to institutions, not to them · program year 2025

Through program year 2025, Alex Nelson of Murray, UT is reported in the CMS Open Payments database as having received $16,581 across 455 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $29,223 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,360 79
2024 General $2,405 89
2023 General $968 65
2022 General $3,770 74
2021 General $1,849 60
2020 General $4,160 44
2019 General $2,070 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alex Nelson
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Alex Nelson were reported at $1,360. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Alex Nelson Interventional Pain Medicine median Middle half National median
2019 $2,070 $684 $216–$2,079 $163
2020 $4,160 $382 $122–$1,109 $114
2021 $1,849 $552 $167–$1,554 $132
2022 $3,770 $605 $187–$1,924 $149
2023 $968 $671 $195–$1,915 $160
2024 $2,405 $684 $206–$1,837 $164
2025 $1,360 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,303 163 payments
  2. Medtronic USA, Inc. $4,111 35 payments
  3. Boston Scientific Corporation $2,876 35 payments
  4. Relievant Medsystems, Inc. $1,146 14 payments
  5. Lundbeck LLC $308 18 payments
  6. Amgen Inc. $270 15 payments
  7. AbbVie, Inc. $263 12 payments
  8. Collegium Pharmaceutical, Inc. $237 15 payments
  9. Lilly USA, LLC $229 15 payments
  10. TerSera Therapeutics LLC $223 8 payments
  11. Other $2,617 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,027 441 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,960 2 payments
  3. Travel and Lodging $3,394 11 payments
  4. Consulting Fee $200 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $3,575 103 payments
  2. LIORESAL $2,500 1 payment
  3. INTELLIS $1,508 28 payments
  4. SUPERION $1,186 7 payments
  5. Intracept Pain $860 6 payments
  6. Intracept Pain $860 6 payments
  7. INCEPTIV $406 32 payments
  8. Intracept Pain $302 9 payments
  9. NURTEC ODT $298 15 payments
  10. Intracept Pain $277 7 payments
  11. Other $5,223 280 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,110

Median for Neurology: 833

Drug cost

$105,870

Median for Neurology: $202,670

Branded share of claims

40%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 18 $25,212
Emgality Pen Galcanezumab-Gnlm Brand 29 $20,177
Glatiramer Acetate Generic 11 $15,266
Oxtellar Xr Oxcarbazepine Brand 15 $11,420
Xtampza Er Oxycodone Myristate Brand 14 $5,614
Movantik Naloxegol Oxalate Brand 12 $5,150
Buprenorphine Generic 22 $4,917
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 126 $4,011
Gabapentin Generic 96 $1,949
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 114 $1,762

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$228,483

Of which drugs: $822

Medicare patients

414

Average age 73

Services billed

3,844

259 women, 155 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 40%
Chronic kidney disease 33%
Ischemic heart disease 27%
Diabetes 26%
Heart failure 21%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 84 1,029 $780
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 27 380 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
  • Lundbeck LLC $126
$126 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $53
$53 14 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $45
$45 — —
KISUNLA
  • Lilly USA, LLC $42
$42 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

455 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record